Intensity Therapeutics company info

What does Intensity Therapeutics do?
Intensity Therapeutics (NASDAQ:INTS) is a biotech firm deeply engaged in the development of immunotherapy treatments aimed at a variety of cancers. The company's unique approach involves directly injecting its drug candidates into solid tumors to stimulate an immune response that targets cancer cells throughout the body. Among its notable projects is INT230-6, designed to improve the effectiveness of existing cancer therapies and reduce their side effects. Intensity Therapeutics is keen on transforming cancer treatment by fostering durable responses in advanced and hard-to-treat cancers, demonstrating its commitment to changing the landscape of cancer care through innovation and research.
Intensity Therapeutics company media
Company Snapshot

Is Intensity Therapeutics a public or private company?

key
Ownership
Public

How many people does Intensity Therapeutics employ?

people
Employees
5

What sector is Intensity Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Intensity Therapeutics?

location pin
Head Office
Westport, United States

What year was Intensity Therapeutics founded?

founded flag
Year Founded
2012
What does Intensity Therapeutics specialise in?
/Cancer Treatment /Drug Development /INT230-6 /Clinical Trials /Pharmaceutical Innovations /Patient Care

What are the products and/or services of Intensity Therapeutics?

Overview of Intensity Therapeutics offerings
INT230-6, a lead product designed for direct injection into solid tumors to cause cancer cell death and immune system activation.
Research collaborations with Merck and Bristol-Myers Squibb to test the combination of INT230-6 with key immunotherapies, aiming to improve cancer treatment outcomes.
Development of drug delivery technologies focusing on direct tumor injection, aiming to minimize systemic exposure and side effects.
Pipeline expansion efforts to include novel drug candidates for various types of cancer, leveraging their proprietary drug formulation technology.
Investigation of INT230-6's mechanism of action to inform the development of next-generation cancer therapies and potentially broaden its applicability.

Who is in the executive team of Intensity Therapeutics?

Intensity Therapeutics leadership team
  • Mr. Lewis H. Bender M.A., M.B.A., M.S.
    Mr. Lewis H. Bender M.A., M.B.A., M.S.
    Founder, President, CEO & Chairman of the Board
  • Mr. John  Wesolowski CPA, M.B.A.
    Mr. John Wesolowski CPA, M.B.A.
    Principal Accounting Officer & Controller
  • Mr. James M. Ahlers
    Mr. James M. Ahlers
    Executive Vice President of Corporate Finance
  • Mr. Joseph  Talamo CPA, M.B.A.
    Mr. Joseph Talamo CPA, M.B.A.
    Chief Financial Officer
  • Mr. Brian  Schwartz M.D.
    Mr. Brian Schwartz M.D.
    Executive Vice President of Clinical Development